Nanobody-Based Lateral Flow Assay for Rapid Zika Virus Detection DOI Creative Commons
Yuli Peng,

Atheer Alqatari,

Fabian Kießling

et al.

ACS Synthetic Biology, Journal Year: 2025, Volume and Issue: unknown

Published: March 7, 2025

Zika virus infections remain severely underdiagnosed due to their initial mild clinical symptoms. However, recent outbreaks have revealed neurological complications in adults and severe deformities newborns, emphasizing the critical need for accurate diagnosis. Lateral flow assays (LFAs) provide a rapid, cost-effective, user-friendly method antigen testing at point-of-care, bedside, or home settings. LFAs utilizing nanobodies multiple benefits over traditional antibody-based techniques, as are much smaller, more stable, simpler manufacture. We introduce nanobody-based LFA rapid identification of antigens. Starting from two previously reported recognizing nonstructural protein 1 (NS1), we evaluate periplasmic cytosolic nanobody expression test different purification tags immobilization strategies. quantify binding kinetics validate mutually noncompetitive binding. Avidity effects boost capture tetrameric target by 3 orders magnitude point general strategy higher sensitivity sensing. The detects NS1 with limit detection ranging 25 ng/mL buffer urine. This nanobody-LFA has potential facilitate on-site self-diagnosis, improve our understanding infection prevalence, support public health initiatives regions affected outbreaks.

Language: Английский

Nanobody-Based Lateral Flow Assay for Rapid Zika Virus Detection DOI Creative Commons
Yuli Peng,

Atheer Alqatari,

Fabian Kießling

et al.

ACS Synthetic Biology, Journal Year: 2025, Volume and Issue: unknown

Published: March 7, 2025

Zika virus infections remain severely underdiagnosed due to their initial mild clinical symptoms. However, recent outbreaks have revealed neurological complications in adults and severe deformities newborns, emphasizing the critical need for accurate diagnosis. Lateral flow assays (LFAs) provide a rapid, cost-effective, user-friendly method antigen testing at point-of-care, bedside, or home settings. LFAs utilizing nanobodies multiple benefits over traditional antibody-based techniques, as are much smaller, more stable, simpler manufacture. We introduce nanobody-based LFA rapid identification of antigens. Starting from two previously reported recognizing nonstructural protein 1 (NS1), we evaluate periplasmic cytosolic nanobody expression test different purification tags immobilization strategies. quantify binding kinetics validate mutually noncompetitive binding. Avidity effects boost capture tetrameric target by 3 orders magnitude point general strategy higher sensitivity sensing. The detects NS1 with limit detection ranging 25 ng/mL buffer urine. This nanobody-LFA has potential facilitate on-site self-diagnosis, improve our understanding infection prevalence, support public health initiatives regions affected outbreaks.

Language: Английский

Citations

0